Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial.
Jean-Emmanuel KurtzEric Pujade-LauraineAna OakninLisa BelinKatharina LeitnerDavid CibulaHannelore G DenysOra RosengartenManuel J RodriguesNikolaus de GregorioJerónimo Martínez-GarciaEdgar PetruRoman KocianIgnace VergotePatricia PautierBarbara SchmalfeldtLydia GabaStephan PolterauerMarie-Ange Mouret ReynierJalid SehouliCristina ChurrucaFrédéric SelleFlorence Joly LobbedezVeronique D'HondtÉmilie Bultot-BoissierCoriolan LebretonJean-Pierre LotzRémy LargillierPierre Etienne HeudelFlorian Heitznull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
ATALANTE/ENGOT-ov29 did not meet its coprimary PFS objectives in the ITT or PD-L1-positive populations. OS follow-up continues. Further research on biopsy samples is warranted to decipher the immunologic landscape of late-relapsing OC.